Skip to content

Sacral nerve stimulation or anal bulking therapy for faecal incontinence - a comparative study

Sacral nerve stimulation vs anal bulking for faecal incontinence - a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN00247992
Enrollment
100
Registered
2013-01-10
Start date
2013-03-01
Completion date
Unknown
Last updated
2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Faecal incontinence in adults Digestive System Faecal incontinence

Interventions

Two interventional arms: 1. Sacral nerve stimulation 2. Anal bulking therapy

Sponsors

Sahlgrenska University Hospital (Sweden)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with fecal incontinence with > or = 2 episodes of fecal incontinence/week. 2. > 18 years 3. Insufficient effect of conservative treatment (physiotherphy, diet, drugs). 4. At least one year duration of symptoms 5. At least one year after vaginal delivery 6. Ability to confirm informed consent

Exclusion criteria

Exclusion criteria: 1. Complete external sphincter defect (at least 90 degrees, whole length of the anal canal evaluated by physical examination of ultrasound). 2. Ongoing anorectal infection 3. Active inflammatory bowel disease 4. Anorectal implant. 5. Anorectal surgery within the last 12 months. 6. Mucosal prolaps (gr 3-4) 7. Rectal prolaps 8. Ongoing malignant disease 9. Ongoing immunosuppressive treatment 10. Treatment with warfarin 11. Rectal anastomosis 12. Neurologic disease (MS, ALS, Myelomeningocele etc.) 13. Previous pelvic radiotherphy 14. Ongoing anorectal pain 15. Included in other RCT 16. Pregnancy 17. Previously treated with any of the two alternatives in the study 18. Concurrent condition or disease that makes the person unsutable for the study according clinical jugement of the investigator (eg not likely to follow the study protocol).

Design outcomes

Primary

MeasureTime frame
Responding (> 50% reduction of the number of fecal incontinence episodes compared to baseline) proportion after one year after randomisation.

Secondary

MeasureTime frame
1. Change in number of faecal incontinence episodes 2. Change in deferring time 3. Change in incontinence score 4. Change in Quality of Life 5. Adverse events

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026